• Propanc reported new preclinical PDAC data for PRP showing >90% mean tumor growth inhibition versus vehicle controls (p<0.001).
• Animal studies showed median overall survival extended by more than 2.5-fold versus controls.
• Results also indicated reduced metastatic burden, tumor microenvironment remodeling, and improved sensitivity to gemcitabine/nab-paclitaxel in chemo-resistant cells.
• PRP is a fixed-ratio combination of trypsinogen and chymotrypsinogen with a non-cytotoxic, differentiation-based mechanism; it holds FDA Orphan Drug Designation in pancreatic cancer.
• Development focus shifted to advancing PRP into a planned Phase 1b first-in-human study in 40-45 advanced solid-tumor patients, with pancreatic cancer a key indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Propanc Biopharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270830PRIMZONEFULLFEED9816996) on August 27, 2026, and is solely responsible for the information contained therein.